ArticleJournal of Crohn's & colitis2022
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.
Neil Chanchlani et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
31 papers cite it
this papercites it